|
 |
European Pharmaceutical Contractor
|
Respiratory physicians are buzzing about the number of new asthma drugs being developed by a variety of pharmaceutical companies. This is good news for approximately 155 million people worldwide who are affected by the disease. The prevalence of asthma is increasing, generally thought to be associated with spreading urbanisation and exposure to respiratory toxins - including domestic mites, vehicle exhaust and passive smoking.
Asthma is caused by both host risk factors and environmental risk factors. Host factors include genetic predisposition, atopy, airway hyper-responsiveness, gender, race and ethnicity. Environmental factors which increase susceptibility include indoor and outdoor allergens, tobacco smoke, air pollution, respiratory infections - especially viral disease, family size, diet, drugs, obesity and family pets. Recently there has been much research into asthma but the balance between nature, nurture and the changing environment remains poorly understood. We have a long way to go, but there are the beginnings of new therapies for asthma which offer hope for the future.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
New PFA SonicLineŽ ultrasonic flowmeters
Flow measurement with ultrasound fast, precise, free from contamination The new PFA SonicLineŽ ultrasonic flowmeters assure precise measurement and control of chemical consumption and management of chemical stocks with high reliability. SonicLineŽ is also ideally suited for accurate batch and dosing processes with high reproducibility.
More info >> |
|
 |
